After acquiring a majority stake in ProteoVant last year, South Korea's SK Biopharm is continuing to hunt for new modalities and is now moving into the hot radiotherapeutics area through a deal with Full-Life Technologies.

Celltrion has ticked off another major regulator as it continues to lead the pack of global developers for biosimilar Xolair.

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.

Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.